Back to Journals » ClinicoEconomics and Outcomes Research » Volume 12

Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

Authors Bereza BG, Coyle D, So DY, Kadziola Z, Wells G, Grootendorst P, Papadimitropoulos EA

Received 24 October 2019

Accepted for publication 19 February 2020

Published 19 March 2020 Volume 2020:12 Pages 167—175


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Samer Hamidi

Basil G Bereza, 1 Doug Coyle, 2 Derek Y So, 3 Zbigniew Kadziola, 4 George Wells, 2 Paul Grootendorst, 1 Emmanuel A Papadimitropoulos 1, 4

1University of Toronto Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada; 2University of Ottawa School of Epidemiology and Public Health, Toronto, ON, Canada; 3University of Ottawa Heart Institute, Ottawa, ON, Canada; 4Eli Lilly & Company, Toronto, ON, Canada

Correspondence: Basil G Bereza
Leslie Dan Faculty of Pharmacy, 144 College Street, Toronto, ON M5S 3M2, Canada
Tel +1 416-978-6989

Background: Pharmacogenetic (PGx) testing identifies pharmacotherapeutic risks to permit personalized therapy. Identifying the genetic profile of patients with acute coronary syndrome (ACS) who are considered for therapy with clopidogrel (P2Y 12 receptor blockers) and acetylsalicylic acid (ASA) contributes to the treatment paradigm. Patient preferences would inform a collaborative framework and by extension inform healthcare policy formulation.
Purpose: To quantify stated preferences (willingness to pay) for attributes of a novel point-of-care PGx (CYP2C19) test using a discrete choice experiment (DCE) from the general public in Ontario, Canada, and to identify starting point bias of the cost attribute.
Methods: A web survey was created and included a questionnaire, decision board, and a DCE. DCE choice sets include the following attributes (levels): sample collection (blood, finger prick, and cheek swab), turnaround time for results (1 hr, 3 days, and 1 week), and cost in additional insurance premiums. The presence of starting point bias (cost attribute levels of $0, $1, $5 or $0, $2, $10) in the estimation of willingness to pay (WTP) was tested.
Results: Estimates for turnaround time and cost attributes were statistically significant. Coefficients related to the starting point bias were also significant. Approximately 67% of survey participants chose the PGx test compared to status quo treatment options. WTP for a 1 hr turnaround time compared to a 1-week turnaround time was $10.77 (95% CI 9.58 -12.25).
Conclusion: This translational study shows preference for a point of care PGx test.

Keywords: discrete choice experiment, pharmacogenetic test, patient preference, starting
point bias

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]